Objective To investigate the application effect of Edaravone Injection in the clinical treatment of patients with acute cerebral infarction. Methods Convenient selection 58 cases of acute cerebral infarction in our hospital from December 2013 to February 2016 were selected and randomly divided into observation group and control group, 29 cases in each group. Control the implementation of routine treatment group, patients in the observation group on the basis of Yiyidala in injection treatment. The clinical efficacy, adverse reaction rates, and ESS and ADL scores of 2 groups were compared. Re-sults In this experiment to observe the groups of patients with clinical total effective rate was 93.1%, compared with the control group of 69%, significant difference with statistical significance (χ2=5.497, P< 0.05); two groups of patients with treatment of ESS and ADL score compared no significant difference (t=0.155 0.166,P> 0.05). The patients in the observa-tion group after the ESS scores and ADL scores were significantly better than the control group, the difference was statisti-cally significant (t=2.961, 4.146, P < 0.05); the incidence of adverse reactions in the observation group rate was 10.3%(serum creatinine increased in 1 cases, elevated transaminases, 1 cases, hematuria in 1 case), compared with the control group of 3.4% (impaired liver function 1 case), comparing the differences between the two groups no statistical significance (χ2=1.074, P>0.05). Conclusion Will the application of edaravone injection in treatment of patients with acute cerebral in-farction can improve the nerve function of patients with and improve the clinical curative effect and no serious adverse reac-tions, it is worth learning from.%目的：探讨依达拉奉注射液在急性脑梗塞患者临床治疗中的应用效果。方法方便选取2013年12月―2016年2月该院收治急性脑梗死患者58例,将其随机分成观察组与对照组各29例。对照组患者实施常规治疗,观察组患者则在此基础上以依达拉奉注射液进行治疗。对2组患者的临床疗效、不良反应发生率及ESS及ADL评分加以对比。结果该试验中,观察组患者临床治疗总有效率为93.1%,相较于对照组的69.0%,差异有统计学意义(χ2=5.497,P<0.05﹚；2组患者治疗前ESS评分与ADL评分对比差异无统计学意义(t=0.155,0.166,P>0.05﹚,观察组患者治疗后其ESS评分与ADL评分则显著优于对照组,差异有统计学意义(t=2.961,4.146,P<0.05﹚；观察组患者不良反应发生率为10.3%(血肌酐升高1例,转氨酶升高1例,血尿1例﹚,相较于对照组的3.4%(肝功能受损1例﹚,组间对比差异无统计学意义(χ2=1.074,P>0.05﹚。结论将依达拉奉注射液应用于急性脑梗塞患者的临床治疗可有效改善患者神经功能,提高临床疗效,且无严重不良反应,值得借鉴。
展开▼
